News & Events

  • May 17, 2017

    National Energy Services Reunited Corp. announced the closing of its initial public offering in the amount of $210,000,000.  EG&S acted as counsel to National Energy.

  • May 16, 2017

    Dextera Surgical Inc. announced the closing of their Underwritten offering in the amount of $7,280,000.  EG&S acted as counsel to the Underwriter.

  • May 12, 2017

    EG&S is representing Fig Publishing, Inc. in Fig’s ongoing, multiple securities offerings under the SEC’s amended Regulation A. Fig is a video game publisher that issues separate series of preferred stock to members of the public, with each series designed to pay dividends based on revenues earned from a separate video game. So far, Fig has sold three series of Regulation A “Fig Game Shares”.

  • May 11, 2017

    Client Alert: New York City Bans All Inquiries Regarding Salary Histories of Job Applicants

    New York City has joined other states and cities across the country – including Massachusetts and Philadelphia – in banning employers from inquiring about a job candidate’s salary history. Per legislation signed on May 4, 2017 by New York City Mayor Bill DeBlasio, effective November 1, 2017, all employers in New York City, both public and private and regardless of size, may no longer:

    (1)        inquire about the salary history of an applicant for employment; or
    (2)        rely on the salary history of an applicant in determining that applicant’s salary at any stage in the employment process, unless the applicant “unprompted” and “willingly” discloses his or her prior salary information.

    Click here to read the alert.

  • May 11, 2017

    Amyris Inc. announced the closing of their Registered Direct offering in the amount of $87,343,875.  EG&S acted as counsel to the Placement Agent.

  • May 03, 2017

    On April 26, 2017, the Appellate Division, Second Department issued a decision reversing the Surrogate of Rockland County who had previously granted petitioner’s motion for summary judgment against EGS client, Alfred Zucaro.  In reversing, the Second Department also granted Mr. Zucaro summary judgment dismissing petitioner’s conversion cause of action against him.

    James K. Landau, a member of the Firm, represented Mr. Zucaro in connection with the appeal.  A copy of the decision can be found at http://law.justia.com/cases/new-york/appellate-division-second-department/2017/2015-02684.html.

  • May 01, 2017

    The Deal issued its quarterly PIPE league tables, revealing that 2017's first quarter outperformed last year's first quarter. Deals were up nearly 75% from the previous year to 367, while dollars raised were up almost 70% to $21.3 billion.

    EG&S is top ranked.  Click here to read the article.

  • May 01, 2017

    CytRx Corporation announced the closing of their Registered Direct in the amount of $15,000,000.  EG&S acted as counsel to the Placement Agent.

  • April 28, 2017

    BioPharm X Corporation announced the closing of their Registered Direct offering in the amount of $5,000,001.  EG&S acted as counsel to the lead Investor.

  • April 27, 2017

    Aeterna Zentaris Inc. announced the implementation of their At the Market offering in the amount of $6,944,000.  EG&S acted as counsel to the Placement Agent.

  • April 26, 2017

    Apricus Biosciences, Inc. announced the closing of their Underwritten offering in the amount of $7,042,000.  EG&S acted as counsel to the Underwriter.

  • April 24, 2017

    Sunshine Heart, Inc. announced the closing of their Underwritten offering in the amount of $8,372,000.  EG&S acted as counsel to the Underwriter.

  • April 21, 2017

    Social Reality Inc. announced the closing of their PIPE offering in the amount of $5,000,000.  EG&S acted as counsel to the lead Investor.

  • April 19, 2017

    DelMar Pharmaceuticals, Inc. announced the closing of their Registered Direct offering in the amount of $9,000,000.  EG&S acted as counsel to the Placement Agent.

  • April 18, 2017

    SkyPeople Fruit Juice, Inc. announced the closing of their Registered Direct offering in the amount of $2,672,500.  EG&S acted as counsel to the Placement Agent.

  • April 17, 2017

    Cytori Therapeutics announced the closing of a confidentially marketed public offering of common stock in the amount of $8.8 million.  EG&S acted as counsel to the underwriter, Maxim Group LLC.

  • April 12, 2017

    Forum Merger Corporation, a company formed for the purpose of entering into a merger, share exchange, asset acquisition or other similar business combination with one or more businesses or entities, announced the closing of its initial public offering in the amount of $150,000,000.  EG&S acted as counsel to Forum Merger.

  • April 12, 2017

    Blink Health announced that it has raised a $90 million Series B equity funding led by 8VC, bringing its total venture capital funding to $165 million. Blink Health is a technology platform that enables consumers to access the medications at affordable prices through over 57,000 pharmacies nationwide.  EGS acted as counsel to Blink Health.

  • April 12, 2017

    Catalyst Biosciences Inc. announced the closing of their Underwritten offering in the amount of $18,939,000.  EG&S acted as counsel to the Underwriter.

  • April 10, 2017

    SGOCO Group Ltd. announced the closing of their Registered Direct offering in the amount of $1,000,000. EG&S acted as counsel to the Investor.

  • April 06, 2017

    EKSO Bionics Holdings, Inc. announced the closing of their Registered Direct offering in the amount of $11,719,597.  EG&S acted as counsel to the Placement Agent.

  • April 04, 2017

    ITUS Corporation announced the closing of its rights offering of common shares in the amount of $4,700,000.  EG&S acted as counsel to ITUS.

  • April 03, 2017

    Atossa Genetics Inc. announced the closing of their Underwritten offering in the amount of $4,397,500.  EG&S acted as counsel to the Underwriter.

  • April 03, 2017

    Dynatronics Corporation announced the closing of their PIPE in the amount of $9,000,000.  EG&S acted as counsel to the Placement Agent.

  • March 31, 2017

    Biocept Inc. announced the closing of their Registered Direct offering in the amount of $9,296,672.  EG&S acted as counsel to the lead Investor.